Direct compression of Asthmaspray Actuator Pharma Grade API into immediate-release tablets is specified for formulations where the active load falls between 0.5 wt% and 5.0 wt% of the core compound. The route is limited by segregation forces in high-speed rotary presses: if API D90 exceeds 20 µm, the blend may stratify during transfer from the bin blender to the press hopper, generating superpotent tablets in the first compression stations and low-assay tablets after 45 min of continuous running. To maintain blend uniformity, the API is pre-delumped through a 0.5 mm stainless steel screen and combined with a base of microcrystalline cellulose at 30–60 wt%, lactose monohydrate at 20–50 wt%, croscarmellose sodium at 2.0–4.0 wt%, and magnesium stearate at 0.5–1.0 wt%. Lubricant addition is confined to the final 3 min of blending at 10–20 rpm in a bin blender filled to 60% capacity; extended lubrication reduces tablet tensile strength and raises dissolution variability under USP <711> testing. Acceptance criteria follow USP General Chapter <905> Uniformity of Dosage Units, USP <701> Disintegration, 21 CFR 211.165, and ICH Q3D elemental impurity controls. Tablet compression is performed at 10–20 kN main compression force, with hardness maintained at 60–80 N, friability below 1.0%, and disintegration below 15 min. The terminal finished dosage form is an immediate-release oral tablet packaged in PVC-aluminum blisters.

What Drives Tamping-Pin Capsule Fill Weight Variation Across Long Production Campaigns?

In hard gelatin or hypromellose capsule production, fill weight variation is controlled primarily by powder bed density and pin compression force rather than by the API assay alone. When dose strengths below 10 mg are encapsulated, the filled powder formulation contains Asthmaspray Actuator Pharma Grade API at 0.5–10.0 wt%, pregelatinized starch at 10–30 wt%, anhydrous lactose at 30–70 wt%, and sodium stearyl fumarate at 0.5–1.5 wt%; magnesium stearate is commonly restricted at higher levels because it slows wetting and can extend disintegration beyond 15 min. In tamping-pin capsule fillers operating at 60,000–100,000 capsules/h, a powder bed depth below 40 mm causes first-layer underfill and upper capsule body splitting, while a bed depth above 80 mm raises the occurrence of overfilled capsule caps and machine jam faults. Compaction force settings on the tamping pins are held between 50–200 N, with in-process checkweighing rejection limits of ±5.0%. When batch-to-batch API particle size shifts of ±2 µm D50 are observed, fill weight correction is made through pin compression adjustment rather than reformulation. Compliance is anchored to USP <905>, USP <711>, Ph. Eur. 2.9.40, 21 CFR 211.110, and ICH Q3D. Terminal product types include oral hard capsules in sizes 1–3 with unit weights of 250–500 mg, compatible with PVC-PVDC and alu-alu blister packaging.

High-Shear Wet Granulation Endpoint Control and Drying Uniformity Limits

When API with low bulk density, high cohesiveness, or poor flow is processed at active loads above 5.0 wt%, high-shear wet granulation is selected to reduce segregation risk and improve downstream compression. The process is run in a 600 L high-shear granulator with impeller speed 100–200 rpm and chopper speed 1500–3000 rpm. Dry mixing proceeds for 2 min before purified water is added at 5 kg/min to a final water content of 20–30% w/w; the granulation endpoint is determined by impeller torque 25–35 N·m or power draw 8–12 kW, not by fixed granulation time. Over-wetting beyond 35% w/w produces paste-like mass that clogs the 1.0 mm conical mill screen during sizing, while under-wetting below 15% w/w yields wet cakes with excessive fines migration and poor densification. The formulation contains the API at 1.0–10.0 wt%, hypromellose as binder at 2.0–5.0 wt%, lactose monohydrate at 50–80 wt%, and crospovidone at 2.0–5.0 wt%, with half of the disintegrant added intragranularly and half extragranularly. Wet mass is dried in a fluid-bed dryer with inlet air at 60°C to a loss-on-drying endpoint of 1.5–2.5%; residual moisture above 3.0% causes tablet picking and reduces dissolution stability, while overdrying below 1.0% increases granule friability and capping. Process controls follow 21 CFR 211.110, ICH Q7, and USP <905> for finished solid oral units. Terminal product types include compressed tablets, granules for sachet, and granule-based hard capsules.

Because aqueous injectable contact raises hydrolysis and trace metal leaching risks before terminal sterilization, the Asthmaspray Actuator Pharma Grade API is evaluated in forced degradation screening under oxygen, heat, and light stress before the injectable solution route is fixed. The formulated solution is prepared in Water for Injection under nitrogen purging to dissolved oxygen below 0.5 mg/L, with active concentration controlled at 0.1–10.0 mg/mL, pH adjusted to 6.0–7.4 using citrate or phosphate buffer at 10–50 mM, and osmotic pressure adjusted with sodium chloride or mannitol to 280–320 mOsm/kg. The solution is passed through a 0.22 µm PVDF sterilizing filter into USP Type I borosilicate vials, and filter integrity is verified by bubble point before fill. Terminal sterilization in a water-spray autoclave is performed at 121°C for 15 min with heat penetration acceptance F0 ≥ 12 min. The process window is constrained by pH shifts caused by buffer degradation and by trace metal leaching from 316L stainless steel mixing vessels; if the solution contacts stainless steel for more than 8 h before fill, iron levels can exceed 100 ppb, requiring chelation or vessel passivation. Where supplier stability data for this specific injectable configuration are limited, a laboratory terminal-sterilization feasibility batch is required before scale-up. Compliance includes USP <1> Injections, USP <788> Particulate Matter, USP <790> Visible Particulates, USP <85> Bacterial Endotoxins, USP <1207> Container Closure Integrity, 21 CFR 211.167, and ICH Q3D elemental impurity limits. Finished dosage forms are sterile injectable solutions in single-dose vials or ampoules for intravenous or intramuscular administration.

Lyophilized Injectable Powder Requires Residual Moisture and Glass Transition Control Beyond Sterility

Instability of the injectable API in aqueous solution or the need to eliminate cold-chain distribution commonly triggers selection of lyophilization over liquid-fill injection. The pre-lyophilization solution contains the API at 1.0–10.0 mg/mL, mannitol at 2.0–5.0% w/v as a crystallizing bulking agent, and trehalose or sucrose at 5.0–10.0% w/v as an amorphous stabilizer; total solid content above 20% w/v increases cake collapse and primary drying time. The solution is frozen at 0.5–1.0°C/min to -40°C, annealed at -10°C for 2–5 h to complete mannitol crystallization, then primary-dried at shelf temperature -20 to -30°C and chamber pressure 50–200 mTorr. Product temperature must remain below the collapse temperature of the amorphous phase; if the drying front exceeds the collapse threshold by 2°C, macro-collapse generates high residual moisture and slow reconstitution. Secondary drying is performed at 25–40°C for 6–12 h until Karl Fischer moisture is below 1.0%. Compliance is tested against USP <71> Sterility Tests, USP <85> Bacterial Endotoxins, USP <921> Water Determination, USP <922> Water Activity, and 21 CFR 211.166 stability testing; container closure integrity follows USP <1207>. Where published data for this specific API in lyophilized configuration are limited, a freeze-thaw screening with modulated differential scanning calorimetry is used to identify the collapse boundary before defining the production cycle. Terminal dosage forms are lyophilized powders for injection in Type I glass vials sealed with bromobutyl rubber stoppers, reconstituted in Water for Injection or saline before administration.

When Oral Liquid Dosage Forms Demand Solubility Enhancement and Antimicrobial Preservation

In populations with swallowing impairment, oral liquid preparation of Asthmaspray Actuator Pharma Grade API is specified because tablet or capsule intake is not feasible. The solution or suspension is formulated at an active concentration of 0.05–5.0 mg/mL, with citrate or phosphate buffer at 10–50 mM to maintain pH 5.0–6.5, sorbitol or glycerol at 20–35% w/v as sweetness and viscosity modifiers, and sodium benzoate at 0.1–0.2% w/v or methylparaben at 0.05–0.1% w/v as preservative. The API is dissolved or dispersed in purified water at 25–35°C with propeller mixing at 500–1000 rpm; suspension settling is controlled by adding xanthan gum at 0.1–0.3% w/v, which maintains yield stress without preventing pouring. The liquid is passed through a 0.45 µm pre-filter and filled into amber polyethylene terephthalate bottles under nitrogen headspace to limit oxidative degradation. Antimicrobial effectiveness is validated under USP <51>; purity and stability testing follow 21 CFR 211.194, USP <1231> Water for Pharmaceutical Purposes, and ICH Q3D elemental impurity limits. Finished product types include oral solutions, oral suspensions, and unit-dose oral liquid sachets with fill volumes of 5–30 mL.